Royal Bank Of Canada Has Lowered Expectations for Evolent Health (NYSE:EVH) Stock Price

Evolent Health (NYSE:EVH) had its target price dropped by research analysts at Royal Bank Of Canada from $5.00 to $3.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the technology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential downside of 3.69% from the company’s current price.

Several other equities analysts have also recently issued reports on the stock. Zacks Research upgraded shares of Evolent Health from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Piper Sandler set a $6.00 price objective on shares of Evolent Health in a report on Tuesday, December 2nd. Citizens Jmp cut their price objective on Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a report on Tuesday, January 6th. Citigroup decreased their price target on shares of Evolent Health from $9.50 to $6.00 and set a “buy” rating on the stock in a research report on Friday, January 9th. Finally, JPMorgan Chase & Co. cut their price objective on Evolent Health from $13.00 to $7.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.85.

Evolent Health Stock Up 21.7%

Shares of Evolent Health stock traded up $0.56 on Wednesday, reaching $3.12. The company’s stock had a trading volume of 1,530,148 shares, compared to its average volume of 2,863,869. The company has a market capitalization of $347.63 million, a price-to-earnings ratio of -1.95 and a beta of 0.27. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 1.25. Evolent Health has a 52 week low of $2.50 and a 52 week high of $12.06. The firm’s fifty day simple moving average is $3.54 and its two-hundred day simple moving average is $5.87.

Institutional Investors Weigh In On Evolent Health

Several large investors have recently bought and sold shares of EVH. Nisa Investment Advisors LLC raised its position in shares of Evolent Health by 88.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,551 shares of the technology company’s stock valued at $29,000 after purchasing an additional 1,194 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Evolent Health by 4,000.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock valued at $35,000 after purchasing an additional 4,000 shares in the last quarter. Strs Ohio acquired a new stake in shares of Evolent Health during the 1st quarter valued at about $47,000. Vise Technologies Inc. purchased a new stake in shares of Evolent Health in the fourth quarter valued at approximately $50,000. Finally, Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Evolent Health during the 3rd quarter worth approximately $51,000.

Evolent Health News Summary

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 EPS beat estimates — Evolent reported $0.08 EPS vs. the Zacks consensus $0.06, improving from a loss a year ago; this shows operational leverage on the bottom line. Earnings Beat
• Positive Sentiment: Business growth areas highlighted — Management called out strong oncology growth and strategic initiatives on the Q4 call that could support longer-term revenue expansion and client renewals. Q4 Call Highlights
• Neutral Sentiment: Revenue roughly in line with expectations — Q4 revenue of $468.7M was essentially flat with consensus ($468.48M) but was down ~27.5% year-over-year, indicating near-term top-line pressure despite the EPS beat. Earnings Release
• Neutral Sentiment: FY2026 revenue guidance centered around consensus — The company issued revenue guidance in a $2.4B–$2.6B range that maps to the market’s expectations (consensus ~ $2.4B); guidance reduces downside surprise risk but is not a clear upside catalyst. Press Release
• Negative Sentiment: Analyst downgrade from KeyCorp — KeyCorp cut Evolent from “overweight” to “sector weight,” a bearish signal that likely contributed to selling pressure. KeyCorp Downgrade
• Negative Sentiment: Price-target cut by BTIG — BTIG lowered its target from $10 to $8 (still a “buy”), reducing implied upside and investor enthusiasm. BTIG Target Cut
• Negative Sentiment: Weak top-line trend and margins — Revenue fell ~27.5% YoY and the company reported a negative net margin, which keeps near-term fundamentals under scrutiny despite the EPS beat. Metrics Analysis

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.